Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

LABORATORY CORPORATION OF AMERICA HOLDINGS

(LH)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
11/22/2021 11/23/2021 11/24/2021 11/26/2021 11/29/2021 Date
283.76(c) 285.91(c) 283.73(c) 289.3(c) 292.7643 Last
491 226 329 969 271 502 622 083 92 787 Volume
+0.16% +0.76% -0.76% +1.96% +1.20% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 15 894 M - -
Net income 2021 2 284 M - -
Net Debt 2021 3 290 M - -
P/E ratio 2021 12,3x
Yield 2021 -
Sales 2022 14 400 M - -
Net income 2022 1 308 M - -
Net Debt 2022 2 976 M - -
P/E ratio 2022 21,2x
Yield 2022 -
Capitalization 27 686 M 27 686 M -
EV / Sales 2021 1,95x
EV / Sales 2022 2,13x
Nbr of Employees 68 780
Free-Float 99,4%
More Financials
Company
Laboratory Corporation of America Holdings is a life sciences company that provides clinical laboratory and end-to-end drug development services. The CompanyÔÇÖs business segments include Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). Through its Dx and DD segments, the Company provides diagnostic, drug development and technology enabled solutions. The Company also supports clinical trial activity in... 
More about the company
Ratings of Laboratory Corporation of America Holdings
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about LABORATORY CORPORATION OF AMERICA HOLDINGS
11/18Labcorp to Acquire Contract Research Firm Toxikon for Undisclosed Sum
MT
11/18Labcorp to Acquire Toxikon, Expanding Nonclinical Development Testing Capabilities for ..
BU
11/18LABORATORY CORPORATION OF AMERICA HO : LH) entered into a definitive agreement to acquire ..
CI
11/12Laboratory Corp. Reportedly in Discussions to Combine Certain Assets With Syneos Health
MT
11/04Labcorp and National Kidney Foundation Promote Patient Registry to Enhance Clinical Tri..
BU
11/04Labcorp and National Kidney Foundation Promotes Patient Registry to Enhance Clinical Tr..
CI
11/02LABCORP TO SPEAK AT CREDIT SUISSE 30TH ANNUAL HEALTHCARE CONFERENCE - Form 8-K
PU
11/02Labcorp to Speak at Credit Suisse 30th Annual Healthcare Conference
BU
11/02LABORATORY CORP OF AMERICA HOLDINGS MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL ..
AQ
11/01Dr. Marcia Eisenberg, Labcorp Diagnostics Chief Scientific Officer, Named to Fierce Hea..
BU
11/01Credit Suisse Lifts Price Target on Laboratory Corp. of America Holdings to $338 From $..
MT
10/29Morgan Stanley Adjusts Price Target on Laboratory Corp of America Holdings to $377 From..
MT
10/28Labcorp Announces 2021 Third Quarter Results Company Raises Full-Year Guidance - Form 8..
PU
10/28Laboratory Corporation of America Holdings Revises Earnings Guidance for the Full Year ..
CI
10/28TRANCHE UPDATE ON LABORATORY CORPORA : LH)'s Equity Buyback Plan announced on February 7, ..
CI
More news
News in other languages on LABORATORY CORPORATION OF AMERICA HOLDINGS
11/18Labcorp va acquérir la société de recherche sous contrat Toxikon pour une somme non div..
11/12Laboratory Corp. Serait en discussion pour combiner certains actifs avec Syneos Health
10/28Laboratory Corporation of America Holdings révise ses prévisions de résultats pour l'an..
10/28Baisse du bénéfice ajusté de Labcorp au 3e trimestre, hausse du chiffre d'affaires et r..
10/28Earnings Flash (LH) LABCORP affiche un chiffre d'affaires de 4,06 milliards de dollars ..
More news
Analyst Recommendations on LABORATORY CORPORATION OF AMERICA HOLDINGS
More recommendations
Stock Trading Strategies
LABORATORY CORPORATION OF AMERICA HOLDINGS - 06/30
Close to a key resistance level
BUY
More Stock Trading Analysis
Chart LABORATORY CORPORATION OF AMERICA HOLDINGS
Duration : Period :
Laboratory Corporation of America Holdings Technical Analysis Chart | LH | US50540R4092 | MarketScreener
Technical analysis trends LABORATORY CORPORATION OF AMERICA HOLDINGS
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 17
Last Close Price 289,30 $
Average target price 329,79 $
Spread / Average Target 14,0%
EPS Revisions
Managers and Directors
Adam H. Schechter Chairman, President & Chief Executive Officer
Glenn Andrew Eisenberg Chief Financial Officer & Executive Vice President
Lance V. Berberian Chief Information & Technology Officer & EVP
Brian J. Caveney Chief Medical Officer, EVP & President-Diagnostics
Stephen M. Anderson Chief Scientific Officer-Covance & Senior VP
Sector and Competitors